ARTICLE | Product Development
Where Tanox will take its HIV program
October 25, 1993 7:00 AM UTC
After languishing for almost two years,Tanox Biosystems Inc.'s anti-HIV monoclonal antibodies have been returned to the company by partner Ciba-Geigy Ltd.
Ciba completed a Phase I/II Swiss trial in 12 late-stage AIDS patients in October 1991 and reported on the safety of the lead compound, AIDS-439, at the 1992 AIDS meeting in Amsterdam. But according to David Anderson, executive vice president and COO, a reorganization of Ciba's worldwide R&D resulted in the departure of the product's champion and a planned Phase II trial never commenced. AIDS-439 is directed against the V3 loop of the gp120 envelope protein of the IIIb laboratory strain of HIV...